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Available online 11 October 2018Background: PAIS exhibits a complex spectrum of phenotypes and pubertal outcomes. The paucity of reliable
prognostic indicators can confoundmanagement decisions including sex-of-rearing.We assessedwhether exter-
nal masculinisation score (EMS) at birth or functional assays correlates with pubertal outcome in PAIS patients
and whether the EMS is helpful in sex assignment.
Methods:We collected pubertal outcome data for 27 male-assigned PAIS patients, all with conﬁrmed androgen
receptor (AR) mutations, including two previously uncharacterized variants (I899F; Y916C). Patients were
grouped as follows; EMS at birth b5 and ≥ 5 (EMS in normalmales is 12;median EMS in PAIS is 4·7) and pubertal
outcomes compared.
Findings: Only 6/9 patients (67%) with EMS b5 underwent spontaneous onset of puberty, versus all 18 patients
with EMS ≥5 (p = .03). Only 1/6 patients (17%) with EMS b5 developed adult genitalia reaching Tanner stage
4 or 5, versus 11/13 (85%) with EMS ≥5 (p=0·01). There was no signiﬁcant difference between the two groups
of patients in being prescribed androgen replacement, who reached adult testicular volume ≥ 15 ml, pubic hair
Tanner stage 4 or 5, above average adult height, had gynaecomastia, and mastectomy. No correlation was
observed between EMS and in vitro AR function.
Interpretation: In PAIS with ARmutation, birth EMS is a simple predictor of spontaneous pubertal onset and sat-
isfactory adult genitalia. This provides useful information when discussing the likely options for management at
puberty.
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in silicomodelling1. Introduction
Androgen insensitivity syndrome (AIS) is themost common cause of
undermasculinisation in XY males with a disorder of sex development
(DSD) when characterised by a phenotype consistent with androgenen insensitivity
; SDS, standard
action domain;
bridge, Level 8,
Kingdom.
e under the CC BY-NCresistance [3–5]. The complete form (CAIS) is characterised by a female
phenotype, while the partial form (PAIS) is expressed as a variablemale
phenotype. This includes hypospadias, micropenis, biﬁd scrotum and
undescended testes at birth, or in later life, gynaecomastia and infertility
as a result of oligospermia or azoospermia in amalewith otherwise nor-
mal genitalia.
CAIS is invariably caused by a mutation in the androgen receptor
(AR) gene,whereas a pathogenicARmutation is found in only 22% of pa-
tients with a PAIS-like phenotype [6]. Consequently, it is important to
exclude other conditions which can present with a similar XY DSD phe-
notype when undertaking studies in PAIS. Demonstrating an ARmuta-
tion which was conﬁrmed to be pathogenic as a cause of the PAIS
phenotype was a requirement for inclusion of cases for this present-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
There are limited data on pubertal outcome in patients with partial
androgen insensitivity syndrome (PAIS) assigned male at birth.
We searched PubMed using the search term “(‘androgen insensi-
tivity’ AND (partial NOT complete)) AND (‘long term’ OR ‘follow
up’ OR pubert* OR outcome)” (last searched in June 2018).
After review, we could only identify two relevant articles [1,2].
One study reported pubertal outcome in 14 PAIS patients, all of
whom had an external masculinisation score (EMS) of 5 or more,
thus excluding information on the more severely
undermasculinised infants at birth [1]. A more recent study re-
ported pubertal outcome in a larger group of 29 males with a
provenARmutation and a range of EMS at birth [2]. A specific fea-
ture of this study was the universal finding of pubertal
gynaecomastia.
Added value of this study
The paucity of outcome data at puberty makes it difficult to pre-
dict what will happen at puberty in boys with PAIS particularly
when there is severe undermasculinisation of the external genita-
lia at birth. This study analysed prospectively collected data on
EMS at birth and function of AR mutations in 27 PAIS patients
to determine whether useful predictors of puberty outcome
could be identified. The cohort included two patients withARmu-
tations (I899F and Y916C) for which functional studies had not
previously been undertaken. All 18 patients who had EMS ≥5 at
birth had spontaneous onset of puberty,whereas three of nine pa-
tients whose EMS b5 at birth failed to start puberty spontane-
ously. In contrast to the clinical findings, there was no clear
predictor of puberty outcome from the functional analysis of AR
variants.
Implications of all the available evidence
Our study indicates that in PAIS patients with a confirmedARmu-
tation, the EMS at birth is a simple predictor of spontaneous pu-
bertal onset and adult genital development. Consistent with
recent reports of gynaecomastia prevalence in PAIS [1,2], thema-
jority of patients in this study developed the problem at puberty
and irrespective of their EMS at birth. Consideration should be
given to selectively starting an anti-estrogen or aromatase inhibi-
tor in early puberty. Functional analysis of AR mutations in vitro
provided detailed information to explain the PAIS phenotype but
was not as predictive as clinical findings for puberty outcome.
However, these assays together with in silico modelling of AR
structure may prove beneficial in guiding optimal treatment in
those patients requiring high dose androgen treatment.
402 N. Lek et al. / EBioMedicine 36 (2018) 401–409study and knowledge of ARmutation status is important to guide man-
agement of PAIS in the longer term [2].
Sex assignment at birth for an infant with DSD is a central compo-
nent of management undertaken jointly by health professionals and
the family. In PAIS characterised by severe undermasculinisation, a
key question raised is whether masculinisation is likely to occur at pu-
berty. Data on such outcomes are limited [1,2]. Consistent ﬁndings ap-
pear to be a variable degree of spontaneous masculinisation at
puberty, theneed for androgen supplements to inducepuberty in nearly
half the cases, and the frequent occurrence of gynaecomastia.
There is a trend in recent decades towardsmale sex-of-rearing for all
causes of XY DSD, including PAIS infants who are severelyundermasculinised [7]. This poses a challenge of formulating predictive
factors which inform puberty and subsequent development in early
adulthood inmales.Wehypothesised that the degree ofmasculinisation
at birth as assessed by a validated external masculinisation score (EMS)
[8] and functional analysis of the cognate mutant ARwould be clinically
informative. Thus, clinical follow-up data and the results of in vitro func-
tional studies for 19 unique ARmutations within the study cohort were
analysed, including two previously uncharacterised ARmutants (I899F
and Y916C) for which preliminary structure/function analysis is
presented.2. Patients and methods
2.1. Patients
The Cambridge DSD Database contains detailed information on each
case based on a questionnaire completed by the referring clinician at the
timeof notiﬁcation.Using this resource, 27 PAIS patientswere identiﬁed
with known AR mutations characterised functionally who were
assigned male and were of pubertal or post-pubertal age at the last
known clinical assessment.2.2. Clinical data
Information on the external genitalia at birth was veriﬁed and
further information on the status of pubertal development was ob-
tained via a second questionnaire distributed to their current clini-
cian following written informed consent from the patient and/or
parents. The questionnaire was completed opportunistically during
a routine clinic visit. The pubertal data were collected in binary
format (yes/no): spontaneous onset of puberty; whether androgen
replacement was given; testicular volume ≥ 15 ml (as assessed
using Prader Orchidometer); Tanner stage 4 or 5 for pubic hair
and genitalia (penile length was not measured consistently, with
‘satisfactory penile development’ often recorded); ﬁnal adult
height standard deviation score (SDS) ≥ 0 (i.e. taller than the aver-
age adult male in the UK using 1990 UK population reference);
presence of gynaecomastia and whether mastectomy was per-
formed. Data on testosterone and gonadotrophin concentrations
were available in only 10 subjects, thereby an insufﬁcient number
for analysis in this study. The degree of virilisation at birth was
quantiﬁed by the EMS [8]. The composite EMS ranges from a min-
imum of 0 (indicating complete lack of masculinisation) to a max-
imum of 12 (normal masculinisation).
The median EMS among all PAIS patients raised male in the Cam-
bridge DSD Database (n= 41) is 4·7. The 27 patients in this study co-
hort were sub-divided into 2 groups based on an EMS at birth b5
(belowmedian) and ≥ 5 (at or abovemedian). The clinical data collated
at puberty and beyond were compared between the two groups and
analysed using Fisher's exact test for categorical variables as being the
appropriate test for the relatively small sample size; statistical signiﬁ-
cance was taken to be p b 0·05.2.3. PAIS-associated AR mutations
Genomic DNA was isolated from peripheral leukocytes or genital
skin ﬁbroblasts using standard techniques. The coding exons and
exon/intron boundaries of the AR gene were analysed by direct se-
quencing. Amino acid numbering for the human AR (1\\920) is based
on NM_000044.2 (NCBI). A total of 19 unique ARmutations were iden-
tiﬁed in the study cohort, which were assessed for their impact on AR-
dependent reporter activation. Two previously uncharacterised variants
were also assessed for dimerization and coactivator binding in yeast
two-hybrid assays [9].
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Wild-type (WT) human AR cDNA expression vector pSVAR0 was
used to generate AR mutant expression vectors by QuikChange Site-
Directed Mutagenesis Kit (Agilent Technologies) [10]. All AR constructs
were veriﬁed by sequencing. The luciferase reporter construct pGRE2-
TATA-Luc has been described previously [11]. Renilla luciferase con-
structs pGL4-TK and phRG-TK (Promega) or pCH110 (β-galactosidase)
were used as transfection controls.
2.5. Transient transfection and reporter assays
For AR transactivation studies, COS-1 or HeLa cells were
seeded into 12-well tissue culture plates in Dulbecco's modiﬁed
essential medium (DMEM) containing 2 mM glutamine and 10%
charcoal-stripped serum. Cells were transfected with 250 ng
pGRE2-TATA-Luc, 25 ng pSVAR0 and a control reporter 25 ng
phRG-TK (Renilla Luciferase) or pCH110 (β-galactosidase) as in-
dicated using standard transfection procedures. After 16 h incuba-
tion the cells were exposed to fresh medium containing
0–10 nmol dihydrotestosterone (DHT; Sigma) or the synthetic an-
drogen mibolerone (Steraloids Inc) for a further 24 h. The cells
were then lysed in 500 μl passive lysis buffer (Promega) and the
ratio of ﬁreﬂy to renilla was determined using Nanolight technol-
ogy Alternatively, Dual-light System (Applied Biosystems) was
used to measure Luciferase and β-galactosidase activities. Re-
porter assays were quantiﬁed using a Microplate Luminometer
LB 960 (Berthold).
2.6. Yeast two-hybrid assays
Yeast two-hybrid interaction studies were performed as described
previously using the S. cerevisiae L40 reporter strain transformed with
expression vectors for LexA-SRC1 NID 431–761 (nuclear receptor inter-
action domain) in combinationwith VP16-AR LBD (627–920) [9]. VP16-
AR LBD mutants I899F and Y916C were generated by site-directed PCR
mutagenesis, and constructs were validated by sequencing. For AR-
LBD dimerization assays, LexA-AR-LBD was co-transformed with
VP16-AR expression plasmids. Construct expression levels were deter-
mined by western blotting using antibodies speciﬁc for the LexA
(06–719; Millipore) and VP16 (sc-7546; Santa Cruz) epitopes. Co-
transformants were puriﬁed and grown in selective medium in theTable 1A
Clinical pubertal data for the 9 patients with PAIS Group 1 (EMS at birth b5).
Study participant 1-A 1-B
ARmutation R630W S704G
Codon change 2247C N T 2469 A N G
Clinical features at birth
EMS at birth (0−12) 3 2
Scrotal fusion (0; 3) 0 0
Microphallus (0; 3) 0 0
Urethral meatus (0; 1; 2; 3) 0 0
Right gonad (0; 0.5; 1.0; 1.5) 1.5 1
Left gonad (0; 0.5; 1.0; 1.5) 1.5 1
Last known clinical features
Age (years) at the last assessment 26 31
Spontaneous onset of puberty Yes No
Androgen replacement given Yes Yes
Adult testes ≥ 15 ml No No
Adult pubic hair PH4-PH5 Yes No
Adult genitalia G4-G5 No –
Adult height SDS N 0 No No
Presence of gynaecomastia Yes Yes
Mastectomy done Yes Yespresence of 1 μMMibolerone or vehicle. Reporter β-galactosidase activ-
ities are presented as the mean of three independent clones with error
bars to indicate standard deviations.2.7. Ethical approval
Ethical approval for this study was obtained from the local
research ethics committee (09/H0308/158), and institutional
approval was obtained from the Research and Development
Committee at the Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK.2.8. Role of the funding source
The funders had no role in study design, collection, analysis or inter-
pretation of thedata,writing the report, or thedecision to submit the re-
port for publication.3. Results
3.1. EMS at birth and age of last clinical assessment
Table 1A, 1B shows EMS at birth and pubertal status at the last as-
sessment for each of the 27 study participants in relation to theirARmu-
tation type. The age range at last assessment was 14–44 years. Two of
the participants (2-E and 2-O)were aged 14 years and both had entered
puberty spontaneously but were not contactable at the time of the anal-
ysis. The remaining 25 participants had either recently completed pu-
berty or were in young adulthood.3.2. EMS and AR mutation type
Fig. 1 illustrates the distribution of mutations in the AR gene in this
PAIS cohort. All were missense mutations and located in the DNA-
binding (DBD) or ligand-binding (LBD) domains. There was no associa-
tion between EMS at birth and the nature of themissense mutation. In-
deed, some participants harbouring identical mutations displayed a
widely variable EMS. For example, four participants (1-D, 1-E, 2-F and
2-G) with the same ARmutation (R841C) had an EMS of 1, 4, 5, and 9,
respectively (see Table 1A, 1B).1-C 1-D 1-E 1-F 1-G 1-H 1-I
F755 L R841C R841C I899F # R856H A897E A897E
2624C N G 2880C N T 2880C N T 3057 A N T 3016 G N A 3049C N A 3049C N A
1 1 4 1 3 3 3
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 1 0 0 0 0
0.5 0.5 1.5 0.5 1.5 1.5 1.5
0.5 0.5 1.5 0.5 1.5 1.5 1.5
18 38 18 16 21 15 18
No Yes No Yes Yes Yes Yes
Yes No Yes No Yes No No
Yes – Yes Yes No – Yes
Yes No Yes Yes Yes Yes Yes
Yes No No No No – –
Yes No Yes Yes No Yes Yes
Yes Yes Yes Yes Yes No No
Yes Yes Yes Yes No No No
Table 1B
Clinical pubertal data for the 18 patients with PAIS Group 2 (EMS at birth ≥ 5).
Study participant 2-A 2-B 2-C 2-D 2-E 2-F 2-G 2-H 2-I 2-J 2-K 2-L 2-M 2-N 2-O 2-P 2-Q 2-R
ARmutation I665T F674C D691E F755S Y764C R841C R841C R841H I870M I870M A871V M625 L Y916C
#
A597T A871V L713F
&
L713F
&
L713F
&
Codon change 2353 T
N C
2380 T
N G
2432C
N A
2623 T
N C
2650 A
N G
2880C
N T
2880C
N T
2881 G
N A
2969 T
N G
2969 T
N G
2971C
N T
2232 A
N T
3106 A
N G
2148 G
N A
2971C
N T
2496C
N T
2496C
N T
2496C
N T
Clinical features at birth
EMS at birth (0–12) 6 6 5 8 8 5 9 5 6 6 10 7 5 6 6 8 8.5 9
scrotal fusion (0; 3) 3 0 0 3 3 0 3 0 0 0 3 0 0 0 0 0 3 3
microphallus (0; 3) 0 3 0 0 3 3 3 0 3 3 3 3 0 3 3 3 0 0
urethral meatus (0; 1; 2; 3) 0 0 2 2 1 1 1 2 0 0 1 1 2 0 0 3 3 3
right gonad (0; 0.5; 1.0; 1.5) 1.5 1.5 1.5 1.5 0.5 0.5 1 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1 1 1.5
left gonad (0; 0.5; 1.0; 1.5) 1.5 1.5 1.5 1.5 0.5 0.5 1 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1 1.5 1.5
Last known clinical features
Age (years) at the last
assessment
18 18 31 17 14 17 27 20 18 18 44 21 30 16 14 19 17 16
Spontaneous onset of
puberty
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Androgen replacement
given
– Yes Yes Yes – No – Yes – – No No Yes No – Yes Yes Yes
Adult testes ≥ 15 ml Yes Yes Yes No – Yes No Yes Yes Yes Yes No Yes Yes – No No –
Adult pubic hair
PH4-PH5
Yes Yes – – – Yes Yes Yes Yes Yes – Yes – Yes – Yes Yes Yes
Adult genitalia G4-G5 Yes Yes No – – Yes No Yes Yes Yes – Yes – Yes – Yes Yes Yes
Adult height SDS N 0 – Yes No Yes – No Yes Yes No Yes – No Yes – – Yes Yes –
Presence of
gynaecomastia
Yes Yes Yes Yes – – Yes Yes Yes – Yes Yes Yes Yes – Yes Yes Yes
Mastectomy done – – Yes Yes – – Yes Yes Yes – – No No – – Yes Yes Yes
In this cohort of 27 patients with PAIS, a total of 19 different mutations in the ARwere found.
All the mutations except I899F and Y916C (the ones marked with #) have accompanying data from functional studies for comparison with the clinical pubertal data.
Three siblings with ARmutation L713F (the ones marked with &) were included in the study by Lucas-Herald et al. See reference 2.
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Androgen Receptor (AR) gene
Exon   A:  Transcriptional activation
Exons B-C:  DNA binding
Exons D-H:  Ligand binding
R841C
(1)
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Fig. 1. Scheme of androgen receptor gene. Androgen receptor mutations and patients' EMS at birth (in parentheses) were illustrated. Upper; Group 1 (EMS b 5) and below; Group 2 (EMS
≥5). Mutations I899F and Y916C (marked with #) were characterised in Fig. 3.
405N. Lek et al. / EBioMedicine 36 (2018) 401–4093.3. EMS and pubertal outcome
Table 2 shows a quantitative summary of the study cohort (where
data were available). For comparison of pubertal outcomes, the partici-
pants were sub-divided according to the EMS: Group 1, EMS b5 at birth
(n= 9) and Group 2, EMS ≥5 at birth (n= 18). This cohort of 27 PAIS
patients had a higher median (interquartile range) EMS of 6·0 (3·0 to
7·5), compared to an EMS of 4·8 (3·0 to 6·0) recorded in a previously
published cohort of 36 male-assigned PAIS patients [6] and a median
EMS of 4·7 in all 41 male-assigned PAIS patients recorded in the Cam-
bridge DSD Database. In this study, there was no statistically signiﬁcant
difference between Groups 1 and 2 for age at last assessment. TherewasTable 2
Results of statistical analyses on the clinical pubertal data for the 27 patients with PAIS in the s
Study cohort [median (IQR)] Group 1 (EMS at birth b 5), n = 9 Group 2 (E
EMS at birth (0–12) 3.0 (1.0 to 3.0) 6.0 (6.0 to
Age (years) at last assessment 18.0 (18.0 to 26.0) 18.0 (17.0
Group 1 (EMS at birth b 5), n= 9 Group 2 (E
Pubertal outcomes [binary] Yes No Total data, n [%] ^ Yes N
Spontaneous onset of puberty 6 3 9 [100] 18 0
Androgen replacement given 5 4 9 [100] 8 4
Adult Testes ≥ 15 ml 4 3 7 [78] 10 5
Adult Pubic Hair PH4-PH5 7 2 9 [100] 12 0
Adult Genitalia G4-G5 1 5 6 [67] 11 2
Adult Height SDS N 0 5 4 9 [100] 8 4
Presence of gynaecomastia 7 2 9 [100] 14 0
Mastectomy done 6 3 9 [100] 8 2
Statistical analyses
There was no statistically signiﬁcant difference in the age at last clinical assessment between p
All the 18 patients with EMS at birth ≥ 5 (Group 2) had spontaneous onset of pubertal develop
Only 1 of 6 patients with EMS at birth b5 (Group 1) attained Genitalia Tanner Stage G4 or G5 i
^ Data availability:
In this cohort of 27 patients with PAIS, information on evidence of spermatogenesis was availa
There was fewer availability of pubertal outcome data in Group 2 (EMS ≥ 5) for whether mast
There was a trend towards fewer availability of pubertal outcome data in Group 2 (EMS ≥ 5) fo
Whether Pubic Hair Tanner Stage PH4 or PH5 in adulthood was attained, and whether Height
Differences in data availability between the two groups for the other pubertal outcomes did no
⁎ Mann-Whitney U test was used to test for differences in EMS at birth and age at last clinic
⁎⁎ Fisher's exact test was used to test for differences in pubertal outcome (binary) parametera trend towards less data on pubertal outcome in Group 2, and particu-
larly on whether mastectomy had occurred (p= 0·03). Overall differ-
ences in data availability between the two groups did not reach
statistical signiﬁcance.3.4. Spontaneous onset of puberty
24 of the total cohort of 27 participants (89%) entered puberty
spontaneously, based primarily on evidence of an increase in testicular
volume. There was a statistically signiﬁcant difference in spontaneous
versus non-spontaneous pubertal onset according to the EMS: 6/9tudy cohort.
MS at birth ≥ 5), n = 18 p-value ⁎ (Group 1 + Group 2), n= 27
8.0) b0.001 6.0 (3.0 to 7.5)
to 20.8) 0.53 18.0 (17.0 to 23.5)
MS at birth ≥ 5), n = 18 (Group 1 + Group 2), n = 27
o Total data, n [%] ^ p-value ⁎⁎ Total available data, n [%] ^
18 [100] 0.03 27 [100]
12 [67] 0.67 21 [78]
15 [83] 1.00 22 [81]
12 [67] 0.17 21 [78]
13 [72] 0.01 19 [70]
12 [67] 0.67 21 [78]
14 [78] 0.14 23 [79]
10 [56] 0.63 19 [70]
atients in the two groups.
ment, compared to 6 of 9 patients with EMS at birth b5 (Group 1).
n adulthood, compared to 11 of 13 patients with EMS at birth ≥ 5 (Group 2).
ble in six patients (22%).
ectomy was done (Fisher's exact test; p= .03).
r whether androgen replacement was given,
SDS N0 in adulthood was attained (Fisher's exact test; all p= .07).
t reach statistical signiﬁcance (Fisher's exact test; all p N .10).
al assessment of puberty between patients in the two groups.
s between patients in the two groups.
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compared to all 18 participants with EMS ≥5 (p= 0·03).
3.5. Tanner stage 4 or 5 in adult genitalia
Data on this outcomeparameterwere available in 19/27 participants
(70%). Only 1/6 participants (17%) with EMS b5 had adult genitalia
reaching Tanner stage 4 or 5, compared to 11/13 participants (85%)
with EMS ≥5 (p= 0·01).
For all the other pubertal outcomes, therewas no statistically signiﬁ-
cant difference between Groups 1 and 2 for androgen replacement
(n=21; p=0·67), achieving adult testicular volume ≥ 15ml (n=22;
p=1·00), pubic hair Tanner stage 4 or 5 (n=21; p=0·17), above av-
erage adult male height (n = 21; p = 0·67), development of
gynaecomastia (n= 23; p = 0·14), or mastectomy surgery (n= 19;
p = 0·63). Importantly, among the participants in whom data were
available (n= 23), 21 (91%) developed gynaecomastia irrespective of
the EMS at birth or the type of ARmutation. Two siblings (1-H and 1-I)
with ARmutation A897E showed no gynaecomastia with EMS at birth
of 3 in both.
3.6. EMS and functional analysis of AR mutants
PAIS–associatedmutations in ARmay potentially impact on different
AR functions including expression of the AR gene, stability of the mRNA
or AR protein, or protein functions such as DNA or ligand binding, di-
merization and cofactor binding, nuclear localisation, andFig. 2.A:Reporter assays using extracts of transiently transfectedCOS-1 cells showing dose-dep
variant AR proteins in response to dihydrotestosterone (DHT). B: Reporter assay for A897E watranscriptional activity. As AR transcriptional activity is a readout for
most of these functions, we assessed androgen-dependent reporter
gene activation by wild-type and mutant AR proteins in well-
established reporter assays using transiently transfected cells. Fig. 2 de-
picts reporter gene activation by wild-type and mutant AR proteins in
response to increasing DHT/mibolerone concentrations. Transcriptional
activity of mutant ARs was signiﬁcantly impaired except for R630W,
A597T (Fig. 2A), and for A897E (Fig. 2B). Although these three mutant
ARs show a normal transcriptional response, the associated EMS in the
cognate participants were reduced to 3 (1-A, 1-H and 1-I) and 6 (2-
N). Furthermore, the phenotype at birth as deﬁned by the EMS was ex-
tremely variable (including the four participants with the R841C muta-
tion) and did not correlate with the results of in vitro transcriptional
activation studies. The poor correlation between the speciﬁc pathologic
mutation in the AR sequence and the clinical presentation at birth sug-
gests other factors impact on phenotype.
3.7. Mutant AR activity and spontaneous onset of puberty
The activity of 17 different mutant ARs as based on transactivation
assays in vitro was analysed in relation to whether puberty occurred
spontaneously or not. The data are summarised in Fig. 2 and Table 1A,
1B. Increasing concentrations of DHT or mibolerone were used in the
assay and the transcriptional response of a reporter genewas compared
with the wild-type AR. There was no consistent relationship between
the degree of transcriptional AR deﬁcit and puberty outcome. Mutants
R841H and F674C in participants 2-H and 2-B, respectively, had lowendent activation of an androgen-responsive luciferase reporter gene bywild-type (WT) or
s performed separately using COS-1 cells and mibolerone (Mib).
407N. Lek et al. / EBioMedicine 36 (2018) 401–409transcriptional activity relative to wild-type AR and yet in both cases,
puberty occurred spontaneously. In contrast, mutant S704G identiﬁed
in participant 1-B was similarly transcriptionally inactive and in this in-
stance, puberty did not occur spontaneously and response to androgen
treatment was not satisfactory. Nevertheless, although AR transcrip-
tional activity in reporter assays was invariably reduced in most of the
cohort, only three boys did not enter puberty spontaneously. Mutant
R841C characterised by low transcriptional activity was identiﬁed in
four separate participants of whom three entered puberty spontane-
ously and one did not. The widespread inconsistency between this phe-
notypic marker and the results of AR function assessed in vitro indicates
that the AR functional assays employed here may not be a reliable pre-
dictor of pubertal outcome.
3.8. Structure and function analysis of I899F and Y916C AR variants
Two ARmutations were identiﬁed during our molecular investiga-
tion of this cohort of patients with PAIS who were raised male, namely
I899F (identiﬁed in participant 1-G, Group 1) and Y916C (identiﬁed in
participant 2-M, Group 2) where the variants were previously
uncharacterised. A preliminary analysis of structure and function was
undertaken as part of this study.Fig. 3. A: Reporter assays using extracts of transiently transfected HeLa cells showing dose-depe
variant AR proteins in response tomibolerone. B: Yeast two-hybrid assays to assess cofactor bin
or Y916C constructs with the nuclear receptor interaction domain (NID) of steroid receptor c
indicated. C: Dose response curve in yeast two-hybrid assay comparing interaction of AAD-A
homo-dimerization capabilities of AR LBDWT or AR-LBD I899F constructs. The data shown re
.001 by 2-way ANOVA.Examination of the crystal structures of agonist-bound AR LBD
monomers (PDB: 3L3X, 4OEY) or the AR LBD homodimer (PDB: 5JJM)
in complex with cofactor peptides revealed that the I899 sidechain
forms part of the cofactor binding site whereas the Y916 side chain lies
exposed on an outer surface of the AR LBD, distant from ligand binding,
dimerisation or cofactor binding sites (Supplementary Figs. S1 and S2).
Consistent with this, both ARmutants (I899F and Y916C) displayed re-
duced ability to activate the reporter, compared to wild-type AR, espe-
cially at the low concentration (0·1 nM) of exogenous androgen tested
(Fig. 3A). This effect on activity was more pronounced with ARmutant
I899F. To assess whether these mutations impact on the function of
the AR LBD, we performed yeast two-hybrid studies as described previ-
ously [12]. As shown in Fig. 3B, wild-type AR LBD showed a strong
ligand–dependent interaction with the nuclear receptor interaction do-
main (NID) of the Steroid Receptor coactivator (SRC1), a known cofactor
for AR containing three LXXLL motifs. This interaction was signiﬁcantly
compromised by the I899F substitution (Fig. 3B and C) consistent with
the proximity of the residue to the surface required for both cofactor
binding and N/C domain interactions (Supplementary Fig. S2). In con-
trast the I899F mutation had no signiﬁcant impact on the ability of the
AR LBD to form homodimers in these assays in response to ligand
(Fig. 3D), indicating that other major LBD functions were not affected.ndent activation of an androgen-responsive luciferase reporter gene bywild-type (WT) or
ding by ARproteins. Shown is reporter activity due to interaction of AAD-AR LBDWT, I899F
oactivator 1 protein (DBD-SRC1 NID) in the presence of vehicle or mibolerone (1 μM) as
R LBD WT and I899F proteins with DBD-SRC1 NID. D: Yeast two-hybrid assay assessing
present the mean of triplicates and the error bars indicate standard deviations. *** = p b
408 N. Lek et al. / EBioMedicine 36 (2018) 401–409Western blots conﬁrmed similar expression levels of the wild-type and
mutant AR and SRC1 two-hybrid proteins (Supplementary Fig. S3),
4. Discussion
We report the largest cohort of PAIS patients to date whose puberty
has been systematically characterised and quantitatively analysed in re-
lation to the nature of their ARmutation. All 18 patients with median-
or-higher EMS at birth achieved spontaneous onset of puberty, whereas
three of the nine patients with lower-than-median EMS needed andro-
gen treatment to induce puberty. This conﬁrms the utility of assessing
the degree of virilisation at birth to predict likely spontaneous pubertal
development. The ﬁnding has practical importance in assisting health
professionals and families when discussing the likely options for man-
agement at puberty, particularly in light of the recent trend for male as-
signment in PAIS [7].
Indicators of ﬁnal pubertal progression were also informative. There
was failure to reach Tanner stage 4 or 5 inmore of the PAIS patientswith
low EMS. There were no signiﬁcant differences between the two groups
of PAIS patients with high or low EMS in terms of adult testicular vol-
ume, Tanner staging of pubic hair, adult height and incidence of
gynaecomastia. Sperm analysis had been undertaken in 5 patients all
of whom had oligo/azoospermia (1-A, 1-D, 2-C, 2-G, 2-L). A further pa-
tient was reported to have two children but no additional details were
available (2-K). Overall, the results of this study suggest that the higher
the EMS is at birth themore likely that pubertywill occur spontaneously
with satisfactory genital development.
A previous study from Denmark reported gynaecomastia in 13 of 14
PAIS patients in their cohort [1]. The study group was unusual since
eight patients had a normal EMS at birth and ﬁrst presented in puberty
with gynaecomastia as a sign of PAIS. The authors estimated that their
small cohort accounted for 74% of PAIS patients in Denmark, suggesting
the more severely undermasculinised patients presenting at birth were
not included. A larger study of boys with PAIS through the International
Disorders of SexDevelopment Registry reported universal development
of gynaecomastia at puberty [2]. This also seemed to be the case in our
study apart from two siblings who showed no gynaecomastia. Both
had an EMS of 3 at birth and entered puberty spontaneously. That pu-
bertal gynaecomastia is generally common in PAIS raises the possibility
of preventionwith the use of anti-estrogens and aromatase inhibitors to
avoid surgical reduction mammoplasty [13].
A speciﬁc aspect of the current study was inclusion of patients in
whom not only was the diagnosis conﬁrmed by sequencing the AR
gene, but the pathogenicity of the mutation was also assessed. The re-
sults show that all mutations located in the AR LBD displayed reduced
transcriptional activity as measured in a reporter gene activation
assay. However, this in vitro proﬁle was not sufﬁciently speciﬁc in rela-
tion to clinical parameters such as the EMS andwhether puberty started
spontaneously. Two mutations, A597T and R630W, were located out-
side the LBD and both demonstrated wild-type activity in vitro. A597T
occurs in the DNA-binding domain and was originally reported in two
families with Reifenstein syndrome, a previously used eponymous
term to describe the severe form of PAIS [14]. Subsequent studies
showed this mutation disrupts AR dimerization and hence DNA binding
[14,15]. The R630 residue lies at the DBD-hinge domain boundary and
its role is poorly understood. A mutation in this residue (R629Q using
the former numbering system) was identiﬁed in a prostate cancer pa-
tient with hormone refractory/androgen independent disease and was
revealed to enhance AR transcriptional activation [16]. This suggests
that the substitution of arginine by glutamine, an amino acid of similar
volume, promotes AR function whereas the presence of a bulkier aro-
matic tryptophan side chain cannot be accommodated and thereby dis-
rupts androgen signalling.
A combination of reporter assays, yeast two-hybrid assays and in
silicomodelling was used for functional characterisation of Y916C and
I899F, two novel AR mutations identiﬁed during the course of thisstudy. The results show that I899F compromises the recruitment of
the coactivator, SRC1 and consequently is likely to impair AR-
regulated transcription [17]. Structural data for the LBD in complex
with LXXLL or FXXLFmotifs support this conclusion. I899makes impor-
tant stabilising contacts with the ﬁrst conserved leucine or phenylala-
nine in these motifs that would be sterically disrupted by a
phenylalanine side chain, consistent with the yeast two-hybrid data
(Figs. 3B-3D).
The Y916 residue does not participate in the cofactor binding
site, nor at the recently characterised AR dimerization interface
[18]. However, it may be involved in interactions with other pro-
teins due to its exposed location on the AR LBD surface in both
the monomeric and dimeric structures (Supplementary Fig. S1). A
previous study has shown that Y916 is phosphorylated by Src ki-
nase and that this event is important for recruitment of AR to
chromatin [19]. Disruption of such function is unlikely to be de-
tected in a reporter gene assay. Future studies should address the
developmental regulation of AR phosphorylation as its physiologi-
cal signiﬁcance may have relevance to the timing of pubertal onset
and subsequent progression [20].
Since the phenotype associatedwith PAIS is so variable and pleiotro-
pic in its causation, it is generally accepted that a diagnosis of PAIS
should be conﬁrmed by identifying a mutation in the AR gene [3]. Fur-
thermore, additional studies of the mutant receptor are needed, partic-
ularly when the mutation is novel. While the additional use of yeast
two-hybrid assays provides mechanistic insights into the nature of the
functional defect in AR signalling, it is evident that the use of in vitro as-
says of androgen action used in this study is not sufﬁciently informative
to predict how puberty will develop in PAIS associated with a particular
ARmutation. This may be due to variable responses according to differ-
ent promoters used in reporter gene assays under the conditions
employed [21,22]. The complexity of nuclear receptor coregulator dy-
namics is now well established, where the activity of the receptor itself
is inﬂuenced by theDNAelements bound, togetherwith coregulator ex-
pression and recruitment. Current in vitromethods are likely to be sen-
sitive enough only to detect the most extreme of functional defects.
There are also examples of mosaic expression of ARmutations in PAIS
which can explain variable phenotypes [23–25]. The question of mosa-
icismwas not systematically examined in this study. It is likely to be in-
frequent as in most cases, genital skin ﬁbroblast lines had been
established for androgen binding assays and furthermore, many of the
cases were familial.
The strength of the present study is a relatively large cohort of pa-
tients with PAIS demonstrating a range of EMS values which reliably in-
dicated the likelihood of spontaneous onset of puberty. The outcome
parameters of puberty were generally complete, apart from systematic
evidence of spermatogenesis. Furthermore, the clinical dataset was
coupled with detailed information about the ARmutation identiﬁed in
each patient, including the use of in silico modelling. The propensity
for infants with PAIS now to be more likely assigned male at birth re-
quires a management policy that addresses the clinical challenges
which may be faced at puberty and beyond. The majority of patients
with PAIS assignedmale appear to enter puberty spontaneously. There-
after, androgen supplementation may be required for which it may be
possible to utilise data on AR structure and function as a guide for the
type and dose of androgen preparation.Contributors
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